Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.248 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- New England Journal of Medicine
- Topic
- Inflammatory Bowel Disease
- Field
- Biochemistry, Genetics and Molecular Biology
- Canadian institutions
- University of AlbertaUniversity of CalgaryRobarts Clinical TrialsWestern University
- Funders
- Janssen Research and DevelopmentMerck Sharp and DohmeUCB PharmaSun PharmaTillotts PharmaAmgenSeres TherapeuticsCelltrionGenentechJanssen Scientific AffairsCelgeneBiogenGilead SciencesDr. Falk PharmaPfizerAstraZenecaEli Lilly and CompanyBristol-Myers Squibb
- Keywords
- UstekinumabMedicineCrohn's diseaseMaintenance therapyInterleukin 23Monoclonal antibodyMonoclonalDiseaseImmunologyInterleukinInternal medicineAntibodyCytokineChemotherapyAdalimumab
- Has abstract in OpenAlex
- yes